skip to Main Content
  • This page as PDF
October 25, 2018 12:30 - 1:30 PM ET

Drug Pricing Policy: What’s on the Horizon?


Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.

The recent proposal by the administration to require manufacturers to disclose list prices in direct-to-consumer (DTC) advertising is the latest in a wave of recent policy activity focused on prescription drugs at the state and federal levels. This includes noteworthy activity such as allowing indication-based formularies in Part D and step therapy in Medicare Advantage, soliciting feedback on new models to manage Part B drugs, and state efforts to manage Medicaid drug costs. So what’s next?

Avalere experts recap recent policy action and preview future policy activity focused on prescription medications. This webinar provides insights into potential changes, market impacts, and considerations for healthcare stakeholders.

Topics covered:

  • Potential action on management of physician-administered drugs
  • Manufacturer rebates
  • State management of drugs in Medicaid
  • Part D reforms


Elizabeth Carpenter , Head of Advisory Services

Elizabeth Carpenter is the head of Advisory Services.

Matt Brow , President & General Manager - Pharmacy, Life Sciences & Advisory

Matt Brow serves as the president and general manager of Inovalon’s Pharmacy, Life Sciences and Advisory business.

Miryam Frieder , Practice Director, Policy

Miryam Frieder co-leads the Policy Practice.

Lance Grady , Practice Director, Commercialization & Regulatory Strategy

Lance Grady leads the Market Access Practice.

Milena Sullivan , Principal, Policy

Milena Sullivan advises life sciences clients on the impact of the evolving healthcare policy landscape on their commercial, access, and advocacy priorities.

From beginning to end, our team synergy
produces measurable results. Let's work together.
Back To Top